Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

By Pfeiffer Per   Nielsen Dorte   Yilmaz Mette   Iversen Anja   Vejlø Christian   Jensen Benny Vittrup  

Acta Oncologica, Vol. 46, Iss. 5, 2007-01 ,pp. : 697-701

Informa Healthcare

Access to resources Recommend Favorite

Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin

By                                    

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1029-1034

Science Publishers

Access to resources Recommend Favorite

Impact of third-line treatment with irinotecan plus cetuximab on non-tumor standardized uptake values in patients with metastatic colorectal cancer

By        

Oncology Letters, Vol. 4, Iss. 1, 2012-01 ,pp. : 131-134

Spandidos Publications

Access to resources Recommend Favorite

MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer

By Paule Bernard  

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1066-1072

Humana Press, Inc

Access to resources Recommend Favorite

Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer

By Qvortrup Camilla   Jensen Benny Vittrup   Jorgensen Trine Lembrecht   Nielsen Dorte   Bjerregaard Jon Kroll   Pfeiffer Per  

Acta Oncologica, Vol. 49, Iss. 6, 2010-08 ,pp. : 833-836

Informa Healthcare

Access to resources Recommend Favorite